SWOG clinical trial number
SWOG-9217

Chemoprevention of Prostate Cancer with Finasteride (Proscar®), Phase III, Intergroup

Closed
Phase
Accrual
100%
Published
Abbreviated Title
PROSTATE CANCER PREVENTION TRIAL
Activated
10/13/1993
Closed
12/06/1996

Treatment

Finasteride

Eligibility Criteria Expand/Collapse

Finasteride vs Placebo

Eligibility for enrollment: male, >= 55 years, PS=0, DRE within normal limits, no prior prostate ca, no prior finasteride or anabolic steroids, no prior systemic therapy for cancer, must not be in urinary retention or have urinary obstructive symptoms or severe prostatism.


CANCER CONTROL CREDIT: 1.0

Publication Information Expand/Collapse

2018

The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials

JM Unger;W Barlow;CM Tangen;SD Ramsey;IM Thompson;EA Klein;M LeBlanc;CD Blanke;P Goodman;LM Minasian;DL Hershman Cancer Epidemiology Jun 21;55:117-122

PMid: PMID29936140 | PMC number: PMC Journal - In Process

Associations between genetic polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial

L Tang;M Platek;S Yao;C Till;P Goodman;C Tangen;Y Wu;E Platz;M Neuhouser;F Stanczyk;JK Reichardt;R Santella;A Hsing;W Figg;SM Lippman;IM Thompson;CB Ambrosone Carcinogenesis, Feb 9;39(2):125-133; 2017 Dec 8. [Epub ahead of print]

PMid: PMID29228205; PMC Journal - In Process

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

T Dadaev;E Sanders;P Newcombe;C Tangen;P Goodman;IM Thompson;D Albanes;C Haiman;R Eles;D Conti;Z Kote-Jarai Nature Communications Jun 11;9(1):2256

PMid: PMID29892050 | PMC number: PMC5995836

Using Medicare claims to examine long-term prostate cancer risk of Finasteride on the Prostate Cancer Prevention Trial

J Unger;D Hershman;C Till;C Tangen;W Barlow;SD Ramsey;P Goodman;IM Thompson Journal of the National Cancer Institute Mar 9 [Epub ahead of print]

PMid: PMID29534197; PMC Journal - In Process

Circadian Genes and Risk of Prostate Cancer in the Prostate Cancer Prevention Trial

LW Chu;C Till;B Yang;C Tangen;P Goodman;K Yu;Y Zhu;S Han;A Hoque;C Ambrosone;I Thompson;R Leach;A Hsing Molecular Carcinogenesis Mar;57(3):462-466; Jan 10 [Epub ahead of print]

PMid: PMID29318656 | PMC number: PMC5840353

A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma among African Americans

Z Du;K Rand;C Song;P Good;E Klein;J Zonder;R Orlowski;C Haiman;W Cozen American Association for Cancer Research, poster, abst. 223

A Pooled Analysis of Dietary Fiber Intake and Risk of Prostate Cancer

E Sidahmed;SJ Freedland;M Wang;K Wu;J Genkinger;S Smith-Warner American Association for Cancer Research, poster, abst. 5255

Prostate cancer meta-analysis of more than 140,000 men identifies 63 novel prostate cancer susceptibility loci

F Schumacher;AA Al Olama;S Berndt;C Tangen;P Goodman;IM Thompson;D Albanes;C Haiman Nature Genetics Jun 11;9(1):2256

PMid: PMID29892016 | PMC number: PMC5995836

Case-only analyses for identifying genotypes that modify the effect of finasteride in the Prostate Cancer Prevention Trial (PCPT): SWOG S9217

JY Dai;M Leblanc;P Goodman;MS Lucia;I Thompson;C Tangen J Clin Oncol 36, 2018 (suppl; abstr 1551); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster

Reduced Risk of Prostate Cancer With 5a-Reductase Inhibitors. [Editorial]. https://www.ncbi.nlm.nih.gov/pubmed/?term=thompson+i+Reduced+Risk+of+Pr…

IM Thompson;P Goodman;C Tangen Journal of the National Cancer Institute Mar 14. doi: 10.1093/jnci/djy038. [Epub ahead of print]

PMid: PMID29547919

Chemoprevention in Prostate Cancer: Current Perspective and Future Directions [Opinion]

J Ricardo Rivero;IM Thompson;M Liss;D Kaushik Cold Spring Harbor Perspectives in Medicine 2018 Jan 8. pii: a030494. doi: 10.1101/cshperspect.a030494. [Epub ahead of print]

PMid: PMID29311128 | PMC number: n/a

Low free testosterone and prostate cancer risk: a collaborative analysis of 20 prospective studies

EL Watts;P Appelby;A Perez-Cornago;H Bas Bueno-de-Mesquita;J Chan;C Chen;et al. European Urology, Aug 1 [Epub ahead of print]

PMid: PMID: 30077399

Mechanisms and Funding Opportunities in Genitourinary Cancer Clinical Research

C Ryan Urologic Oncology: Seminars and Original Investigations, Jul 31 [Epub ahead of print]

PMid: PMID30072304

2017

A pooled analysis of 15 prospective cohort studies on the association between fruit, vegetable, and mature bean consumption and risk of prostate cancer

J Petimar;KM Wilson;K Wu;D Albanes;P van den Brandt;MB Cook;GG Giles;GE Goodman;P Goodman;N Haansson;K Helzlsouer;L Kolonel;L Liao;S Mannisto;M McCullough;R Milne;M Neuhouser;Y Park;EA Platz;N Sawada;J Schenk Kisser;S Tsugane;B Verhage;M Wang;Y Wang;L Wilkens;R Ziegler;S Smith-Warner;J Schenk Cancer Epidemiology Biomarkers & Prevention Aug;26(8):1276-1287; Apr 26 [Epub ahead of print]

PMid: PMID28446545 | PMC number: PMC5540798

Interactions of the insulin-like growth factor axis and vitamin D in prostate cancer risk in the Prostate Cancer Prevention Trial

FL Miles;P Goodman;C Tangen;KC Torkko;J Schenk;X Song;IM Thompson;M Pollak;M Neuhouser Nutrients Apr 12;9(4). pii: E378. doi: 10.3390/nu9040378

PMid: PMID28417914 | PMC number: PMC5409717

Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial

D Winchester;C Till;P Goodman;C Tangen;R Santella;T Johnson-Pais;R Leach;J Xu;SL Zheng;IM Thompson;MS Lucia;SM Lippman;HL Parnes;WB Isaacs;AM De Marzo;CG Drake;EA Platz Prostate Jun;77(8):908-919

PMid: PMID28317149 | PMC number: PMC5400704

The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials

J Unger;W Barlow;C Tangen;S Ramsey;IM Thompson;EA Klein;M Leblanc;C Blanke;P Goodman;L Minasian;D Hershman J Clin Oncol 35, 2017 (suppl; abstr 1541); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session

Associations between genetic polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial

L Tang;ME Platek;S Yao;C Till;P Goodman;C Tangen;Y Wu;E Platz;ML Neuhouser;F Stanczyk;JK Reichardt;RM Santella;A Hsing;WD Figg;SM Lippman;IM Thompson;CB Ambrosone Proceedings of the American Association for Cancer Research April Vol 58, abst.1274, page 328; AACR Annual Meeting (April 1-5, 2017, Washington, DC), poster

A prospective study of chronic inflammation in benign prostate tissue and risk of prostate cancer: Linked PCPT and SELECT Trials

E Platz;I Kulac;J Barber;C Drake;C Joshu;W Nelson;MS Lucia;SM Lippman;HL Parnes;IM Thompson;P Goodman;CM Tangen;A De Marzo Cancer Epidemiology, Biomarkers and Prevention Oct;26(10):1549-1557; 2017 Jul 28 [Epub ahead of print]

PMid: PMID28754796 | PMC number: PMC5626618

A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry (African-American Multiple Myeloma Study (AAMMS)) Identifies Suggestive Risk Variants

Z Du;K Rand;C Song;N Weinhold;A Huang;X Sheng;D Van Den Berg;A Nooka;S Ailawadhi;S Singhal;E Peters;K Pawlish;N Janakiraman;H Terebelo;C Bock;A Morbacher;M Tomasson;M Fiala;J Mehta;R Kittles;B Rybicki;JL Stanford;P Goodman;S Berndt;J Carpten;V Horn;A Stram;G Casey;L Chu;W Diver;A Hennis;EM John;E Klein;R Orlowski;D Conti;C Haiman;W Cozen American Society of Hematology, poster, abst. 3058A

Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry

D Conti;K Wang;X Sheng;J Bensen;D Hazelett;MB Cook;A Hsing;P Goodman;IM Thompson;EA Klein;BE Henderson;C Haiman Journal of the National Cancer Institute Aug 1;109(8)

PMid: PMID29117387 | PMC number: PMC5448553

Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men

E Watts;P Appleby;D Albanes;A Black;JM Chan;C Chen;P Goodman;JK Parsons;EA Platz;JM Schenk Kisser;IM Thompson;T Key PLoS One Dec 27;12(12):e0187741

PMid: PMID29281666 | PMC number: PMC5744924

2016

Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis

D Winchester;B Gurel;C Till;P Goodman;C Tangen;R Santella;T Paris-Johnson;RJ Leach;IM Thompson;J Xu;S Zheng;MS Lucia;SM Lippman;H Parnes;W Isaacs;CD Drake;A De Marzo;E Platz Prostate, May;76(6):565-574

PMid: PMID26771888 | PMC number: PMC4841624

Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial

H Chen;X Liu;C Brendler;D Ankerst;RJ Leach;PJ Goodman;MS Lucia;CM Tangen;L Wang;F-C Hsu;J Sun;AK Kader;WB Isaacs;BT Helfand;SL Zheng;IM Thompson;EA Platz;J Xu Prostate Sep;76(12):1120-1129

PMid: PMID27197965 | PMC number: PMC5501387

Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial

JM Schenk;C Till;A Hsing;F Stanczyk;Z Gong;M Neuhouser;JK Reichardt;A Hoque;W Figg;P Goodman;CM Tangen;IM Thompson Cancer Causes and Control, Feb;27(2):175-182

PMid: PMID26589415 | PMC number: PMC4724283

Non-steroidal anti-inflammatory drug use not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial

D Patel;J Schenk Kisser;A Darke;J Myers;W Brant;J Hotaling British Journal of Urology International, Mar;117(3):500-506

PMid: PMID26269564 | PMC number: PMC4826049

Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial

T Murtola;B Gurel;M Umbehr;MS Lucia;IM Thompson;P Goodman;A Kristal;HL Parnes;SM Lippman;S Sutcliffe;S Peskoe;JR Barber;CG Drake;WG Nelson;AM DeMarzo;EA Platz Cancer Epidemiology, Biomarkers & Prevention Mar;25(3):463-469

PMid: PMID26715424 | PMC number: PMC4779655

Association of androgen metabolism gene polymorphisms with steroid hormone concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial

DK Price;CH Chau;C Till;P Goodman;RJ Leach;TL Johnson-Pais;A Hsing;A Hoque;H Parnes;J Schenk;CM Tangen;IM Thompson;JK Reichardt;WD Figg Cancer Aug 1;122(15):2332-2340; 2016 May 10 [Epub ahead of print]

PMid: PMID27164191 | PMC number: PMC4956504

Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: a pooled analysis of 15 prospective cohort studies

K Wu;D Spiegelman;Tao Hou;D Albanes;NE Allen;S Berndt;P van den Brandt;G Giles;E Giovannucci;A Goldbohm;G Goodman;P Goodman;N Hakansson;M Inoue;T Key;L Kolonel;S Mannisto;M McCullough;M Neuhouser;AR Kristal;Y Park;E Platz;G Severi;R Sinha;MJ Stampfer;V Stevens;S Tsugane;K Visvanathan;A Wolk;R Ziegler;S Smith-Warner International Journal of Cancer May 15;138(10):2368-2382

PMid: PMID26685908 | PMC number: PMC4837898

Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to finasteride in the Prostate Cancer Prevention Trial

D Winchester;C Till;P Goodman;C Tangen;R Santella;R Leach;J Xu;S Zheng;I Thompson;M Lucia;S Lippman;H Parnes;W Isaacs;A De Marzo;C Drake;E Platz American Association for Cancer Research Annual Meeting (April 16 - 20, 2016, New Orleans, LA), abst #812, poster

Long-term consequences of intervention following receipt of finasteride or placebo in the Prostate Cancer Prevention Trial (SWOG S9217)

J Unger;C Till;I Thompson;C Tangen;P Goodman;J Wright;W Barlow;S Ramsey;L Minasian;D Hershman Journal of the National Cancer Institute Aug 26;108(12). pii: djw168. doi: 10.1093/jnci/djw168.

PMid: PMID27565902 | PMC number: PMC5241895

Peripheral zone inflammation is not strongly associated with lower urinary tract symptom incidence and progression in the placebo arm of the Prostate Cancer Prevention Trial

I Kulac;B Gumuskaya;C Drake;B Gonzalez;K Arnold;P Goodman;A Kristal;MS Lucia;IM Thompson;WB Isaacs;AM De Marzo;E Platz Prostate Nov;76(15):1399-1408; 2016 Jun 21 [Epub ahead of print]

PMid: PMID27325488 | PMC number: PMC5497457

Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors. Results from two large randomized clinical trials

C Tangen;P Goodman;C Till;J Schenk Kisser;MS Lucia;IM Thompson Journal of Clinical Oncology Dec 20;34(36):4338-4344. Epub 2016 Oct 28

PMid: PMID27998216 | PMC number: PMC5455311

A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate risk

R Travis;P Appleby;RM Martin;JMP Holly;D Albanes;A Black;HB Bueno-de-Mesquita;JM Chan;C Chen;MD Chirlaque;MB Cook;M Deschasaux;JL Donovan;L Ferrucci;P Galan;G Giles;E Giovannucci;M Gunter;LA Habel;FC Hamdy;K Helzlsouer;S Hercberg;RN Hoover;J Janssen;R Kaaks;T Kubo;T Kubo;L Le Marchand;EJ Metter;K Mikami;JK Morris;D Neal;M Neuhouser;K Ozasa;D Palli;M Pollak;E Platz;AJ Price;MJ Roobol;C Schaefer;J Schenk;G Severi;M Stampfer;P Stattin;A Tamakoshi;C Tangen;M Touvier;NJ Wald;N Weiss;R Ziegler;TJ Key;NE Allen Cancer Research Apr 15;76(8):2288-2300; 2016 Feb 26 [Epub ahead of print]

PMid: PMID26921328 | PMC number: PMC4873385

A Genetic Contribution to Prostate Cancer Incidence in Men of African Ancestry

CA Haiman;DV Conti;ELLIPSE GAME-ON Consortium American Society of Human Genetics Meeting (Oct 18-22, 2016, Vancouver, BC), poster presentation

Evolving recommendations on prostate cancer screening [Review]

OW Brawley;IM Thompson;H Gronberg American Society for Clinical Oncology Educational Book 35:e80-7

PMid: PMID27249774

Selenium and prostate cancer: analysis of individual participant data from fifteen prospective studies

NE Allen;RC Travis;PN Appleby;D Albanes;MJ Barnett;A Black;H Bueno-de-Mesquita;M Deschasaux;P Galan;G Goodman;P Goodman;M Gunter;M Heliovaara;J Helzlsouer;BE Henderson;S Hercberg;P Knekt;LN Kolonel;C Lasheras;J Linseisen;EJ Metter;M Neuhouser;A Olsen;V Pala;EA Platz;H Rissanen;ME Reid;M Schenk;M Stampfer;P Stattin;C Tangen;M Touvier;A Trichopoulou;P van den Brandt;TJ Key Journal of the National Cancer Institute Jul 6;108(11)

PMid: PMID27385803 | PMC number: PMC5241899

A pooled analysis of glycemic index and load and prostate cancer risk

E Sidahmed;SJ Freedland;M Wang;K Wu;JM Genkinger;SA Smith-Warner American Institute for Cancer Research (Nov 14-16, Bethesda, MD), poster

2015

Effect of finasteride on serum androstenedione and risk of prostate cancer within the Prostate Cancer Prevention Trial: differential effect on high and low grade disease

A Hoque;S Yao;C Till;AR Kristal;P Goodman;AW Hsing;CM Tangen;EA Platz;FZ Stanczyk;JK Reichardt;A vanBokhoven;ML Neuhouser;R Santella;WD Figg;DK Price;HL Parnes;SM Lippman;C Ambrosone;IM Thompson Urology Mar;85(3):616-620

PMid: PMID25733274 | PMC number: PMC4348556

Prospective study of human herpes virus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial

S Sutcliffe;C Till;FJ Jenkins;C Gaydos;P Goodman;A Hoque;A Hsing;IM Thompson;WG Nelson;A De Marzo;E Platz Cancer Causes and Control 26(1):35-44

PMid: PMID25359302 | PMC number: PMC4282945

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial

CH Chau;DK Price;C Till;P Goodman;X Chen;RJ Leach;TL Johnson-Pais;A Hsing;A Hoque;C Tangen;L Chu;H Parnes;JM Schenk;JK Reichardt;IM Thompson;WD Figg PLOS ONE 2015 May 8;10(5):e0126672

PMid: PMID25955319 | PMC number: PMC4425512

Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng/mL, normal DRE, and negative for prostate cancer

MH Umbehr;B Gurel;B Murtola;S Sutcliffe;SB Peskoe;C Tangen;P Goodman;IM Thompson;SM Lippman;MS Lucia;HL Parnes;CG Drake;WG Nelson;AM De Marzo;EA Platz Prostate Cancer and Prostatic Diseases, Sep;18(3):264-269

PMid: PMID25939516 | PMC number: PMC4537352

Serum carotenoid concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial

S Nash;C Till;X Song;EA Platz;JM Schenk Experimental Biology 2015 Conference (March 28-April 1, 2015, Boston, MA), oral presentation, abst. #406.2;

Association between serum fatty acids and intraprostatic inflammation in the placebo arm of the Prostate Cancer Prevention Trial

S Nash;J Schenk;A Kristal;P Goodman;MS Lucia;MS Lucia;H Parnes;IM Thompson;SM Lippman;B Gurel;A Demarzo;EA Platz Cancer Prevention Research Jul;8(7):590-596

PMid: PMID25926387 | PMC number: PMC4491033

Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial

D Winchester;C Till;P Goodman;C Tangen;R Santella;RJ Leach;J Xu;S Zheng;IM Thompson;MS Lucia;SM Lippman;H Parnes;PJ Dluzniewski;WB Isaacs;AM De Marzo;CG Drake;EA Platz Prostate, Sep;75(13):1403-1418

PMid: PMID26047319 | PMC number: PMC4536102

Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial

D Winchester;C Till;P Goodman;C Tangen;R Santella;RJ Leach;J Xu;S Zheng;IM Thompson;M Lucia;S Lippman;H Parnes;PJ Dluzniewski;W Isaacs;AM De Marzo;CG Drake;EA Platz AACR 2015 Meeting (April 18-22, 2015, Philadelphia, PA), abst. 4605, poster presentation;

Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial

CM Heaphy;G Gaonkar;S Peskoe;CE Joshu;AM De Marzo;MS Lucia;P Goodman;SM Lippman;IM Thompson;EA Platz;AK Meeker Prostate, Aug;75(11):1160-1166 2015

PMid: PMID25893825 | PMC number: PMC4475463

Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial

T Murtola;B Gurel;M Umbehr;MS Lucia;IM Thompson;P Goodman;A Kristal;H Parnes;SM Lippman;S Sutcliffe;S Peskoe;C Drake;W Nelson;A De Marzo;EA Platz American Urological Association Annual Meeting (May 15-19, 2015, New Orleans, LA), poster, abstract #MP4-02

Ongoing use of data and specimens from NCI-sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program (CCOP)

L Minasian;C Tangen;DL Wickerham Seminars in Oncology, Oct;42(5):748-763

PMid: PMID26433556 | PMC number: PMC4593316

Serum retinol and carotenoid concentrations and prostate cancer risk: results from the prostate cancer prevention trial

S Nash;C Till;X Song;MS Lucia;H Parnes;IM Thompson;S Lippman;EA Platz;JM Schenk Cancer Epidemiology, Biomarkers & Prevention, Oct;24(10):1507-1515

PMid: PMID26269564 | PMC number: PMC4592455

Effect of 5a-reductase inhibitor use on mortality from prostate cancer [Editorial/Commentary]

W Figg;I Thompson JAMA Oncology, Jun;1(3):321-322

PMid: PMID26181178 | PMC number: PMC n/a

Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies

T Key;P Appelby;R Travis;D Albanes;A Alberg;A Barricarte;A Black;H Boeing;H Bas Bueno-de-Mesquita;J Chan;C Chen;MB Cook;JL Donovan;P Galan;R Gilbert;G Giles;E Giovannucci;G Goodman;P Goodman;MJ Gunter;FC Hamdy;M Heliovaara;KJ Helzlsouer;BE Henderson;S Hercberg;J Hoffman-Bolton;RN Hoover;M Johansson;K-T Khaw;IB King;P Knekt;LN Kolonel;L Le Marchand;S Mannisto;RM Martin;HE Meyer;AM Mondul;KA Moy;DE Neal;M Neuhouser;D Palli;EA Platz;C Pouchieu;H Rissanen;JM Schenk;G Severi;MJ Stempfer;A Tjonneland;M Touvier;A Trichopoulou;SJ Weinstein;R Ziegler;C Zhou;NE Allen American Journal of Clinical Nutrition, Nov;102(5):1142-1157

PMid: PMID26447150 | PMC number: PMC4625592

2014

Factors Associated with Adherence to an End-of-study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217)

ER Gritz;K Arnold;CM Moinpour;A Burton-Chase;C Tangen;J Probstfield;W See;M Lieber;V Caggiano;S Moody-Thomas;C Szczepanek;A Ryan;S Carlin;S Hill;P Goodman;RM Padberg;L Minasian;F Meyskens;IM Thompson Cancer Epidemiology, Biomarkers & Prevention 23(8):1638-1648;

PMid: PMID25028457 | PMC number: PMC4119542

Enhancing nurse contributions to SWOG clinical trials

L Hansen;C Moinpour;R Ermete Seminars in Nursing Oncology 30(1):26-31;

PMid: PMID24559777 | PMC number: PMC3961058

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial

B Gurel;MS Lucia;IM Thompson;P Goodman;C Tangen;A Kristal;H Parnes;SM Lippman;S Sutcliffe;S Pescoe;C Drake;W Nelson;A DeMarzo;E Platz Cancer Epidemiology, Biomarkers & Prevention 23(5):847-856;

PMid: PMID24748218 | PMC number: PMC4012292

Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial

JM Schenk;C Till;CM Tangen;P Goodman;X Song;KC Torkko;AR Kristal;U Peters;M Neuhouser Cancer Epidemiology, Biomarkers & Prevention 23(8):1484-1493;

PMid: PMID25085836 | PMC number: PMC4120235

Added value of genetic risk score to the Prostate Cancer Prevention Trial (PCPT) risk calculator: findings from the PCPT study

H Chen;J Sun;D Ankerst;C Tangen;WB Isaacs;SL Zheng;P Goodman;IM Thompson;E Platz;J Xu American Urological Association Annual Meeting (May 16-21, 2014 Orlando, FL), abst. MP69-12; moderated poster session;

Statin drug use is not associated with prostate cancer risk in men who are regularly screened

E Platz;C Tangen;P Goodman;C Till;H Parnes;W Figg;D Albanes;M Neuhouser;E Klein;MS Lucia;IM Thompson;AR Kristal Journal of Urology 192(2):379-384;

PMid: PMID24518774 | PMC number: PMC4104140

Prostate Cancer Prevention Trial: Access to a biorepository and the associated clinical data

P Goodman;C Tangen;MS Lucia;IM Thompson American Society of Preventive Oncology Annual Meeting, poster;

Prostate Cancer Prevention Trial risk calculator 2.0: for the prediction of low- vs high-grade prostate cancer

D Ankerst;J Hoefler;S Bock;P Goodman;A Vickers;J Hernandez;LJ Sokoll;M Sanda;J Wei;R Leach;IM Thompson Urology 83(6):1362-1368;

PMid: PMID24862395 | PMC number: PMC4035700

Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies

FL Crowe;P Appleby;R Travis;M Barnett;T Brasky;H Bueno-de-Mesquita;J Chavarro;D English;R Gibson;G Giles;G Goodman;S Henning;R Kaaks;I King;L Kolonel;A Kristal;M Neuhouser;SY Park;G Severi;A Siddiq;D Stampfer;P Stattin;C Tangen;A Tionneland;D Trichopoulos;R Tumino;L Wilkens;T Key Journal of the National Cancer Institute Sep 10;106(9): pii: dju240. Print 2014 Sep.;

PMid: PMID2521020 | PMC number: PMC4188122

Health-related quality of life outcomes in prostate cancer prevention clinical trials

C Moinpour International Society for Quality of Life Research annual meeting (Berlin, Germany, Oct. 15-18, 2014); oral presentation;

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial

W Figg;C Chau;D Price;C Till;P Goodman;Y Cho;M Varella-Garcia;JK Reichardt;C Tangen;R Leach;A van Bokhoven;A Kristal;IM Thompson;MS Lucia Urology 84(1):127-131;

PMid: PMID24824408 | PMC number: PMC4077907

Re: Long-term survival of participants in the Prostate Cancer Prevention Trial

IM Thompson;C Tangen;P Goodman Asian Journal of Andrology May-Jun;16(3):414

PMid: PMID24914438 | PMC number: PMC4023368

2013

Projecting prostate mortality in the PCPT and REDUCE chemoprevention trials

PF Pinsky;A Black;R Grubb;ED Crawford;G Andriole;IM Thompson;H Parnes Cancer 119(3):593-601;

PMid: PMID22893105 | PMC number: PMC3502695

Long-term survival of subjects in the Prostate Cancer Prevention Trial (PCPT)

P Goodman;I Thompson;C Tangen;P Godley;L Ford Journal of Clinical Oncology 31 (suppl 6; abstr 10); ASCO Genitourinary Cancers Symposium 2013 (Feb 14-16, 2013, Orlando, Fl), poster;

Long term survival of participants in the Prostate Cancer Prevention Trial

IM Thompson;P Goodman;C Tangen;H Parnes;L Minasian;PA Godley;MS Lucia;L Ford New England Journal of Medicine 369(7):603-610;

PMid: PMID23944298 | PMC number: PMC4141537

Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the Prostate Cancer Prevention Trial

M Neuhouser;EA Platz;C Till;C Tangen;P Goodman;A Kristal;H Parnes;Y Tao;WD Figg;MS Lucia;A Hoque;AW Hsing;IM Thompson;M Pollak Cancer Prevention Research 6(2):91-99;

PMid: PMID23315596 | PMC number: PMC3565024

Should modest elevations in prostate specific antigen or international prostate symptom score, or their rates of increase over time, be used as surrogate measures of incident benign prostatic hyperplasia?

J Schenk;R Hunter-Merrill;Y Zheng;R Etzioni;R Gulati;C Tangen;IM Thompson;A Kristal American Journal of Epidemiology 178(5):741-751;

PMid: PMID23813705 | PMC number: PMC3755644

Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association Symptom Score

D Ankerst;C Till;A Boeck;P Goodman;C Tangen;I Thompson Urology Nov;82(5):1076-81

PMid: PMID24055241 | PMC number: PMC3874369

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome

AJ Vickers;DD Sjoberg;DP Ankerst;CM Tangen;P Goodman;IM Thompson Cancer 119(16):3007-3011

PMid: PMID23720006 | PMC number: PMC3735626

Prostate cancer prevention: strategies for agent development [Review]

H Parnes;MG House;JA Tanagrea Current Opinion in Oncology 25(3):242-251

PMid: PMID23518594 | PMC number: n/a - review article

Survival in the prostate cancer prevention trial

C Tangen;P Goodman;IM Thompson New England Journal of Medicine 369(20):1968

PMid: PMID24224632 | PMC number: PMC4927191

The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator

D Ankerst;C Till;A Boeck;P Goodman;C Tangen;Z Feng;A Partin;D Chan;L Sokoll;J Kagan;J Wei;IM Thompson Journal of Urology 2013 Jul;190(1):70-76

PMid: PMID23313212 | PMC number: PMC3708069

2012

Finasteride reduces the risk of incident symptomatic benign prostatic hyperplasia

JK Parsons;JM Schenk;KB Arnold;K Messer;K Messer;C Till;IM Thompson;A Kristal European Urology, 61(6):1263-1270;

PMid: PMID22459892 | PMC number: PMC4059403

Health-related quality of life findings for the Prostate Cancer Prevention Trial

CM Moinpour;A Darke;G Donaldson;D Cespedes;J Smith;C Johnson;P Ganz;D Patrick;JE Ware;SA Shumaker;FL Meyskens;IM Thompson Journal of the National Cancer Institute 104(18):1373-1385;

PMid: PMID22972968 | PMC number: PMC3529595

The Prostate Cancer Prevention Trial (PCPT) risk calculator and the relationship between PSA and biopsy outcome

AJ Vickers;DP Ankerst;CM Tangen;P Goodman;IM Thompson Journal of Urology 187, No. 4S, Supplement, e492, #1217; American Urological Association Annual Meeting, oral presentation;

Prospective study of cytomegalovirus serostatus and prostate cancer risk in the prostate cancer prevention trial

S Sutcliffe;C Till;CA Gaydos;FJ Jenkins;P Goodman;A Hoque;AW Hsing;IM Thompson;JM Zenilman;WG Nelson;AM DeMarzo;EA Platz Cancer Causes and Control 23(9):1511-1518;

PMid: PMID25359302 | PMC number: PMC4282945

Associations of serum sex steroid hormones and 5a-androstane-3a,17B-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride

A Kristal;C Till;C Tangen;PJ Goodman;M Neuhouser;F Stanczyk;LW Chu;SK Patel;WD Figg;A van Bokhoven;SM Lippman;A Hsing Cancer Epidemiology Biomarkers and Prevention 21(10):1823-1832

PMid: PMID22879203 | PMC number: PMC3467348

Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial [PMID22759721; PMC3493197]

JM Schenk;GS Calip;C Tangen;P Goodman;JK Parsons;IM Thompson;AR Kristal American Journal of Epidemiology 175(2):

PMid: PMID22759721 | PMC number: PMC3493197

2011

Serum estrogen levels and prostate cancer risk in the Prostate Cancer Prevention Trial: a nested case-control study. PMID 21667068; PMC3139891

S Yao;C Till;A Kristal;P Goodman;A Hsing;C Tangen;E Platz;F Stanczyk;J Reichardt;L Tang;M Neuhouser;R Santella;W Figg;D Price;H Parnes;SM Lippman;IM Thompson;C Ambrosone;A Hoque Cancer Cause and Control 22(8):1121-1131;

Serum phospholipid fatty acids and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PMID21518693; PMC3145396

TM Brasky;E White;M Neuhouser;IM Thompson;X Song;C Till;A Kristal American Journal of Epidemiology 173(12):1429-1439;

Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PMID21335507; PMC3070045

A Kristal;C Till;E Platz;X Song;I King;M Neuhouser;C Ambrosone;IM Thompson Cancer Epidemiology Biomarkers Prevention 20(4):638-646

Finasteride reduces the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial

JK Parsons;J Schenk;K Arnold;K Messer;C Till;IM Thompson;A Kristal AUA Annual Meeting, accepted, oral, late-breaking

Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the Prostate Cancer Prevention Trial. PMID21540324

JM Schenk;AR Kristal;KB Arnold;C Tangen;M Neuhouser;DW Lin;E White;IM Thompson American Journal of Epidemiology 173(12):1419-1428

Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial PMID21771722; PMC3179424

L Tang;S Yao;C Tangen;Y Wu;A Kristal;E Platz;M Neuhouser;F Stanczyk;J Reichardt;R Santella;A Hsing;A Hoque;S Lippman;IM Thompson;C Ambrosone Carcinogenesis 32(10):1500-1506

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection

AJ Vickers;C Till;H Lilja;IM Thompson Journal of the National Cancer Institute 103(6):462-469

Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection [Commentary]

AJ Vickers Journal of the Nationadld Cancer Institute 103(21):1635-1636

2010

Transition of a clinical trial into translational research: the Prostate Cancer Prevention Trial experience. PMID21149329; PMC3058741

P Goodman;CM Tangen;A Kristal;IM Thompson;MS Lucia;EA Platz;WD Figg;A Hoque;A Hsing;M Neuhouser;H Parnes;J Richardt;R Santella;C Till;SM Lippman Cancer Prevention Research 3(12):1523-1533;

Single nucleotide differences (SNDs) in the dbSNP database may lead to errors in genotyping and haplotyping studies. PMC2797835; PMID:19877174

L Musumeci;J Arthur;F Cheung;A Hoque;S Lippman;J Reichardt Human Mutation 31(1):67-73

Human papillomavirus types 16, 18 and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. PMC2820385; PMID: 20142255

S Sutcliffe;R Viscidi;C Till;P Goodman;A Hoque;A Hsing;IM Thompson;J Zenilman;A De Marzo;EA Platz Cancer Epidemiology Biomarkers and Prevention 19(2):614-618

Transparency and reproducibility in data analysis: The Prostate Cancer Prevention Trial. PMC2883301 PMID:20173101

S Baker;A Darke;P Pinsky;H Parnes;B Kramer Biostatistics 11(3):413-418

Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. PMID:19938041

A Kristal;DK Price;JM Schenk;M Neuhouser;S Ockers;DW Lin;WD Figg Prostate 70(6):584-590

Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies. PMID: 20135215

E Platz;S Sutcliffe;AM De Marzo;CG Drake;N Rifai;A Hsing;A Hoque;M Neuhouser;P Goodman;A Kristal Cancer Causes and Control 21(6):847-851

Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. PMC2842217;PMID:20142396

JM Schenk;AR Kristal;M Neuhouser;C Tangen;E White;DW Lin;M Kratz;IM Thompson American Journal of Epidemiology 171(5):571-582

Finasteride modifies the relation between serum c-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PMID:20179296

M Neuhouser;C Till;A Kristal;P Goodman;A Hoque;E Platz;A Hsing;D Albanes;H Parnes;M Pollak Cancer Prevention Research 3(3):279-289

Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. PMID 20332306; PMC2853720

A Hoque;C Ambrosone;P Goodman;C Tangen;A Kristal;MS Lucia;Q Wang;M Kappil;I Thompson;A Hsing;H Parnes;RM Santella Cancer Prevention Research 3(4):478-483

Diet, supplement use, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PMID20693267;PMC2950820

A Kristal;K Arnold;ML Neuhouser;P Goodman;D Albanes;IM Thompson American Journal of Epidemiology 172(5):566-577

Editorial Comment

IM Thompson Urology 75(3):509-510

Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial PMID20952028

DK Price;CH Chau;C Till;P Goodman;CE Baum;SB Ockers;BC English;L Minasian;H Parnes;A Hsing;JK Reichardt;CM Tangen;A Kristal;IM Thompson;WD Figg Journal of Urology 184(6):2297-2302

Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma PMID20724727; PMC2935478

IM Thompson;DP Ankerst;CM Tangen Journal of the National Cancer Institute 102(17):1299-1301

2009

Prostate-specific antigen and its role on the Prostate Cancer Prevention Trial

CM Tangen;PJ Goodman Prostate Cancer Screening, 2nd edition, D. Ankerst, IM Thompson, C Tangen, eds., Humana Press, New York, Ch. 24, pp. 333-348

Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator

DP Ankerst;IM Thompson Prostate Cancer Screening, 2nd edition, DP Ankerst, IM Thompson, C Tangen, Eds., Humana Press, New York, Ch. 12, pp. 195-203.

The performance characteristics of prostate-specific antigen for prostate cancer screening

IM Thompson;DP Ankerst Prostate Cancer Screening, 2nd editiion, DP Ankerst, IM Thompson, C Tangen, eds., Humana Press, New York, Ch. 6, pp. 61-70

Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. PMC2682694;PMID: 19117055.

S Sutcliffe;JF Alderete;C Till;P Goodman;A Hsing;JL Zenilman;AM Demarzo;EA Platz International Journal of Cancer 124(9)2082-2087

Serum adiponectin, c-peptide and leptin and risk of symptomatic beign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial

JM Shenk;AR Kristal;ML Neuhouser;CM Tangen;E White;DW Lin Prostate 69(12):1303-1311

Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial

Z Gong;AR Kristal;JM Schenk;CM Tangen;P Goodman;IM Thompson Cancer 1154(16):3661-3669

The performance of PSA for predicting prostate cancer after a prior negative prostate biopsy

CM Tangen Prostate Cancer Screening, 2nd edition, D Ankerst, IM Thompson, C Tangen, eds., Human Press, New York, NY, ch 7, pp 71-78

Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial (Southwest Oncology Group Study S9217). PMC2877916;PMID:19887582

E Platz;C Till;P Goodman;H Parnes;WD Figg;D Albanes;ML Neuhouser;AR Kristal;EA Klein;IM Thompson Cancer Epidemiology, Biomarkers and Prevention 18(11):2807-2813

Cancer prevention clinical trials: assessing for disparities in recruitment in Hawaii

E Bantum;I Cheng;K Cassel;L Kaopua;J Berenberg Frontiers in Cancer Prevention Research, AACR, abstract #B26, p. 116 (poster presentation)

Chemoprevention of prostate cancer. PMID: 19524966

IM Thompson;CM Tangen;P Goodman;MS Lucia;E Klein Journal of Urology 182(2):499-507

2008

Dietary patterns, supplement use and the risk of symptomatic benign prostatic hyperplasia (BPH): results from the Prostate Cancer Prevention Trial

AR Kristal;KB Arnold;JM Schenk;ML Neuhouser;P Goodman;DF Penson;IM Thompson American Journal of Epidemiology 167(8):925-934

PMid: PMID1823602

Does the level of prostate cancer risk affect cancer prevention with finasteride?

IM Thompson;CM Tangen;HL Parnes;SM Lippman;CA Coltman Jr Urology 71(5):854-857

PMid: PMID18455628 | PMC number: PMC2692669

Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment

Y Song;C Tangen;P Goodman;HL Parnes;MS Lucia;IM Thompson;AR Kristal The Prostate 68:281-286

PMid: PMID18163420

Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial

A Hoque;P Goodman;CB Ambrosone;D Albanes;WD Figg;D Price;W Koop;X Wu;J Conroy;J Reichardt;C Tangen;MS Lucia;T Lehman;RM Santella Urology 71(5):967-970

PMid: PMID18267333 | PMC number: PMC2387066

The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy

IM Thompson;CM Tangen;DP Ankerst;C Chi;MS Lucia;P Goodman;HL Parnes;CA Coltman Journal of Urology 180(2):544-547

PMid: PMID18550097 | PMC number: https://www.ncbi.nlm.nih.gov/pubmed/18550097

Serum steroid and sex hormone binding globulin concentrations and the risk of incident benign prostatic hyperplasia (BPH): Results from the Prostate Cancer Prevention Trial. PMC2387066; PMID: 18267333.

AR Kristal;YJ Song;JM Schenk;KB Arnold;Z Gong;ML Neuhouser;P Goodman;C Tangen;DW Lin;F Stanczyk;IM Thompson American Journal of Epidemiology 168(12):1416-1424

Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the Prostate Cancer Prevention Trial

ML Neuhouser;J Schenk;Y Song;CM Tangen;P Goodman;M Pollak;DF Penson;IM Thompson;AR Kristal Prostate 68(13):1477-1486

PMid: PMID18618736 | PMC number: PMC2564287

Integrating the predictiveness of a marker with its performance as a classifier

MS Pepe;Z Feng;Y Huang;G Longton;R Prentice;IM Thompson;Y Zheng American Journal of Epidemiology 167(3):362-368

PMid: PMID179821157 | PMC number: PMC2939738

Does finasteride affect the severity of prostate cancer? A causal sensitivity analysis

BE Shepherd;M Redman;DP Ankerst Journal of the American Statistical Association 103(484):1392-1404

PMid: PMID20526381 | PMC number: PMC2880822

The Prostate Cancer Prevention Trial and the future of chemoprevention. PMID: 18353157

IM Thompson;CM Tangen;MS Lucia British Journal of Urology International 101(8):933-934

Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention

MS Lucia;A Darke;P Goodman;FG La Rosa;HL Parnes;LG Ford;CA Coltman;IM Thompson Cancer Prevention Research 1(3):167-173

PMid: PMID19138952 | PMC number: NIHMSID551895

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach

M Redman;C Tangen;P Goodman;MS Lucia;CA Coltman;IM Thompson Cancer Prevention Research 1(3):174-181

PMid: PMID: 19138953 | PMC number: PMC2844801

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Consumption of dietary supplements and over-the-counter and prescription medications in men participating in the Prostate Cancer Prevention Trial at an academic medical center

EM Grainger;HS Kim;JP Monk;SA Lemeshow;M Gong;RR Bahnson;SK Clinton Urologic Oncology 26(2):125-132

PMid: PMID18312929

Predicting prostate cancer risk through incorporation of prostate cancer gene 3

DP Ankerst;J Groskopf;JR Day;A Blase;H Rittenhouse;BH Pollack;C Tangen;D Parekh;RJ Leach;IM Thompson Journal of Urology 180(4):1303-1308

PMid: PMID18707724

2007

Longitudinal analysis of sexual function reported by men in the prostate cancer prevention trial

CM Moinpour;AK Darke;GW Donaldson;IM Thompson Jr;C Langley;DP Ankerst;DL Patrick;JE Ware Jr;PA Ganz;SA Shumaker;SM Lippman;CA Coltman Jr Journal of the National Cancer Institute 99:1025-1035

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial

MS Lucia;JI Epstein;PJ Goodman;AK Darke;VE Reuter;F Civantos;CM Tangen;HL Parnes;SM Lippman;F La Rosa;MW Kattan;ED Crawford;LG Ford;CA Coltman Jr;IM Thompson Journal of the National Cancer Institute 99:1375-1383

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection

IM Thompson;CM Tangen;PJ Goodman;MS Lucia;HLParnes;SM Lippman;CA Coltman, Jr Journal of Urology 177:1749-1752

Finasteride decreases the risk of prostatic intraepithelial neoplasia

IM Thompson;MS Lucia;MW Redman;A Darke;FG La Rosa;HL Parnes;SM Lippman;CA Coltman Journal of Urology 178:107-110

Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial

AR Kristal;KB Arnold;JM Schenk;ML Neuhouser;N Weiss;P Goodman;GM Antvelink;DF Penson;IM Thompson Journal of Urology 177:1395-1400

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial

IM Thompson;DP Ankerst;C Chi;PJ Goodman;CM Tangen;SM Lippman;MS Lucia;HL Parnes;CA Coltman, Jr. Journal of Clinical Oncology 25(21):3076-3081

Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence

RD Etzioni;DP Ankerst;NS Weiss;LY Inoue;IM Thompson Journal of the National Cancer Institute 99(20):1510-1515

Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention

E Canby-Hagino;J Hernandez;TC Brand;IM Thompson European Urology 51(1):27-33

Prostate-specific antigen in the early detection of prostate cancer

IM Thompson;D Ankerst Canadian Medical Association Journal 176(13):1853-1858

2006

The prostate cancer prevention trial: design, biases, and interpretation of study results

PJ Goodman;IM Thompson Jr;CM Tangen;JJ Crowley;LG Ford;CA Coltman Jr Journal of Urology 175:2234-2242

Association of erectile dysfunction and subsequent cardiovascular disease

IM Thompson Jr;J Probstfield;C Tangen;P Goodman;C Moinpour;CA Coltman Jr Proc of the AUA, Journal of Urology 175(4) Suppl:429 (#1333)

Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

IM Thompson;DP Ankerst;C Chi;PJ Goodman;CM Tangen;MS Lucia;Z Feng;HL Parnes;CA Coltman, Jr. Journal of the National Cancer Institute 98(8):529-534

Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase

AR Kristal;C Chi;CM Tangen;PJ Goodman;R Etzioni;IM Thompson Cancer 106(2):320-328

Comparison of the operating characteristics of PSA for prostate cancer detection for finasteride and placebo in the Prostate Cancer Prevention Trial

IM Thompson;C Chi;P Goodman;C Tangen;D Pauler Ankerst;MS Lucia;CA Coltman Proc of the AUA, Journal of Urology 175(4) Suppl:152, (#470)

Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevetion trial

Z Gong;ML Neuhouser;PJ Goodman;D Albanes;C Chi;AW Hsing;SM Lippman;EA Platz;MN Pollak;IM Thompson;AR Kristal Cancer Epidemiol Biomarkers Prev 15(10):1977-1983

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer

IM Thompson;C Chi;DP Ankerst;PJ Goodman;CM Tangen;SM Lippman;MS Lucia;HL Parnes;CA Coltman Journal of the National Cancer Institute 98(16):1128-1133

Modeling the effect of a preventive intervention on the natural history of cancer: application to the prostate cancer prevention trial

P Pinsky;R Etzioni;N Howlader;P Goodman;IM Thompson Int Jrnl of Biostatistics 2(1): Art 12. http://www.bepress.com/ijb/vol2/iss1/12

Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification

DP Ankerst;IM Thompson Archivio Italiano di Urologia, 78(4):125-129

A working group classification of focal prostate atrophy lesions

AM De Marzo;EA Platz;JI Epstein;AT Billis;TY Chan;L Cheng;M Datta;L Egevad;D Ertoy-Baydar;X Farre;S Fine;KA Iczkowski;M Ittmann;BS Knudsen;M Loda;A Lopez-Beltran;C Magi-Galluzzi;G Mikuz;R Montroni;E Pikarski;G Pizov;MA Rubin;H Samaratunga;T Sebo;IA Sesterhenn;R Shah;S Signoretti;J Simko;G Thomas;P Troncoso;T Tsuzuki;J van Leenders;XJ Yang;M Zhou;WD Figg;A Hoque;MS Lucia American Journal of Surgical Pathology 30(10):1281-1291

PMid: PMID17001160 | PMC number: n/a

2005

Estimated impact of the prostate cancer prevention trial on population mortality

JM Unger;IM Thompson;M LeBlanc;JJ Crowley;PJ Goodman;LG Ford;CA Coltman Jr Cancer 103(7):1375-1380

Pathological assessment of high grade tumors in the Prostate Cancer Prevention Trial (PCPT)

MS Lucia;A Darke;P Goodman;C Tangen;CA Coltman;IM Thompson Journal of Urology 173(4):451 (#1664)

Prostate specific antigen (PSA) as a predictor of adverse pathological features at prostatectomy in the Prostate Cancer Prevention Trial (PCPT)

MS Lucia;P Goodman;C Tangen;CA Coltman;IM Thompson Journal of Urology 173(4):143 (#525)

The performance characteristics of prostate-specific antigen

IM Thompson;DP Ankerst;C Chi;P Goodman;C Tangen;CA Coltman Jr Journal of Urology 173(4):143 (#526)

Operating characteristics of prostate-specific antigen in men with an initial psa level of 3.0 ng/mL or lower

IM Thompson;DP Ankerst;C Chi;MS Lucia;PJ Goodman;JJ Crowley;HL Parnes;CA Coltman The Journal of the American Medical Association 294(1):66-70

Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.

EA Klein;CM Tangen;PJ Goodman;SM Lippman;IM Thompson Journal of Clinical Oncology 23(30):7460-7466

Erectile dysfunction and subsequent cardiovascular disease

IM Thompson;CM Tangen;P Goodman;JL Probstfield;CM Moinpour;CA Coltman JAMA 294(23):2996-3002

Individual prediction of prostate cancer based on prostate specific antigen

C Chi;D Pauler Ankerst;P Goodman Clinical Trials 2 (Suppl 1):P40

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial

RD Etzioni;N Howlader;PA Shaw;DP Ankerst;DF Penson;PJ Goodman;IM Thompson Journal of Urology 174:877-881

Phase III prostate cancer prevention trials: are the costs justified?

IM Thompson;CM Tangen;EA Klein;SM Lippman Journal of Clinical Oncology 23(32):8161-8164

2004

Implementation of the prostate cancer prevention trial (PCPT)

PJ Goodman;CM Tangen;JJ Crowley;SM Carlin;A Ryan;CA Coltman, Jr.;LG Ford;IM Thompson Controlled Clinical Trials 2:203-222

Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter

IM Thompson;DK Pauler;PJ Goodman;CM Tangen;MS Lucia;HL Parnes;LM Minasian;LG Ford;SM LIppman;ED Crawford;JJ Crowley;CA Coltman Jr New England Journal of Medicine 350(22):2239-2246

Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials

CM Tangen;PJ Goodman;JJ Crowley;IM Thompson Journal of Urology 171:S64-S67

The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies

JM Unger;M LeBlanc;IM Thompson;CA Coltman Jr Urologic Oncology: Seminars and Original Investigations 22:362-368

Prostate cancer chemoprevention: an overview of United States trials

A Barqawi;IM Thompson;ED Crawford Journal of Urology 171:S5-S9

First international conference on chemoprevention of prostate cancer

IM Thompson;D Albanes;JW Basler;ED Crawford;LJ Denis;B Djavan;N Fleshner;TL Johnson-Pais;EA Klein;AR Kristal;MS Lucia;HL Parnes;GA Piazza;EA Platz;BH Pollock;DK Price;JK Reichardt;CM Tangen;AW Tolcher;MC McMann Journal of Urology 171:S3-S4

The prostate cancer prevention trial: the association of study site and participant adherence interventions to the study site end-of-study biopsy rates

S Carlin;P Goodman;C Moinpour;C Tangen Clinical Trials 1 (Suppl 1):P45

2003

The prostate cancer prevention trial: design, status, and promise

IM Thompson;C Tangen;P Goodman World Journal of Urology 21:28-30

The influence of finasteride on the development of prostate cancer

IM Thompson;PJ Goodman;CM Tangen;MS Lucia;GJ Miller;LG Ford;MM Lieber;RD Cespedes;JN Atkins;SM Lippman;SM Carlin;A Ryan;CM Szczepanek;JJ Crowley;CA Coltman Jr New England Journal of Medicine 349:215-224

The prostate cancer prevention trial: did the adherence interventions for the end of study biopsy really work?

S Carlin;P Goodman;C Moinpour;S Hill Controlled Clinical Trials 24(3S):P222

2002

Energy from fat is associated with obesity in US men: results from the prostate cancer prevention trial

J Satia-Abouta;RE Patterson;RN Schiller;AR Kristal Preventive Medicine 34:493-501

Biomarker-based methods for determining non-compliance in a prevention trial

K Gower;DK Pauler;PJ Goodman Controlled Clinical Trials 23(2S):49S-50S(#26)

Biomarker-based methods for determining noncompliance in a prevention trial

DK Pauler;KB Gower;PJ Goodman;JJ Crowley;IM Thompson Controlled Clinical Trials 23:675-685

2001

The prostate cancer prevention trial: current status and lessons learned

IM Thompson;M Kouril;EA Klein;CA Coltman;A Ryan;P Goodman Urology 57(Suppl.4A):230-234

Promoting adherence to the prostate cancer prevention trial end of study biopsy requirement

AM Ryan;P Goodman;S Hill;C Moinpour Controlled Clinical Trials 22(2S):88S(#P71)

Dietary supplement use in the prostate cancer prevention trial: implications for prevetion trials.

ML Neuhouser;AR Kristal;RE Patterson;PJ Goodman;IM Thompson Nutrition and Cancer 39(1):12-18

2000

Television and news print media are effective in recruiting potential participants in a prostate cancer chemoprevention trial.

TDK Chung;II Park;L Ignacio;R Catchatourian;MA Kopnick;E Davison;G Conrad;AM Awan;ED Crawford;S Vijayakumar International Journal of Cancer 90:302-304

Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors.

CM Moinpour;L Lovato;IM Thompson;JE Ware;PA Ganz;DL Patrick;SA Shumaker;GW Donaldson;A Ryan;CA Coltman Journal of Clinical Oncology 18(9):1942-1953

Behavioral science research in the cooperative group setting: the Southwest Oncology Group Experience

CC Gotay;CM Moinpour;S Moody-Thomas;ER Gritz;KS Albain;E DeAntoni;L Hansen;PA Ganz Journal of the National Cancer Institute 92(17):1381-1387

Dietary supplement use in the prostate cancer prevention trial: implications for study findings

ML Neuhouser;AR Kristal;RE Patterson;IM Thompson American Society of Prevention Oncology :#76

Letter to the Editor: RE: RE: Chemoprevention of urological cancer

IM Thompson;CA Coltman Journal of Urology 164(4):1321-1322

Minority recruitment in the prostate cancer prevention trial

CM Moinpour;JO Atkinson;SM Thomas;S Millon-Underwood;C Harvey;J Parzuchowski;LC Lovato;AM Ryan;S Hill;E DeAntoni;ER Gritz;IM Thompson, Jr;CA Coltman, Jr Annals of Epidemiology 10(S8):S85-S91

1999

Prostate cancer prevention trial (PCPT) update.

CA Coltman Jr;IM Thompson Jr;P Feigl European Urology 35:544-547

Letters to the Editor: The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen level

CA Coltman British Journal of Cancer 81(1):184-185

Validity of short food frequency questionnaires used in cancer chemoprevention trials: results from the prostate cancer prevention trial

ML Neuhouser;AR Kristal;D McLerran;RE Patterson;J Atkinson Cancer Epidemiology Biomarkers & Prevention 8:721-725

1998

Army and Air Force leadership in the prostate cancer prevention trial.

J Allerton;T Seay;S Optenberg;CA Coltman Jr;B Higgins;I Thompson;L Lovato Urology 51(Suppl.4A):64-66

1997

Chemoprevention of prostate cancer: The prostate cancer prevention trial.

IM Thompson;CA Coltman Jr;J Crowley The Prostate 33:217-221

Utility of the enrollment period in the prostate cancer prevention trial (PCPT).

PJ Goodman;L Lovato;A Ryan;J Crowley;C Moinpour;I Thompson Controlled Clinical Trials 18(S3)(#19):52S

Data operations management with clinical datafax: The prostate cancer prevention trial (PCPT) experience.

AM Ryan;L Emel;P Goodman Controlled Clinical Trials 18(S3)(#P74):156S

Clinical Trials: A Congressional Focus of Need.

CA Coltman, Jr. The Oncologists [Guest Editorial] 2(4):vii-viii

1996

The prostate cancer prevention trial: Efforts to increase the recruitment of minority participants.

CM Moinpour Poster for Conf on the Recruit and Retention of Min Parts in CCR 1/26-27/96 :

Prostate cancer prevention trial.

BH Zoltick Presented at the AUAA Annual Assembly-Orlando Florida May 4-7 :

Screening for prostate cancer: Opportunities for prevention.

IM Thompson;CA Coltman Jr Seminars in Urologic Oncology 14(2)(Suppl.2):4-11

Chemoprevention of prostate cancer with finasteride.

I Thompson;P Feigl;C Coltman Principles and Practice of Oncology 10(3):1-18

The prostate cancer prevention trial.

A Ryan Prevention/Early Detection SIG Newsletter 6(3):1

1995

Design of the prostate cancer prevention trial (PCPT)

P Feigl;B Blumenstein;I Thompson;J Crowley;M Wolf;BS Kramer;CA Coltman Jr;OW Brawley;LG Ford Controlled Clinical Trials 16:150-163

Chemoprevention of prostate cancer with finasteride

I Thompson;P Feigl;C Coltman Important Advances in Oncology, JB Lippincott Co :57-76

Chemoprevention of prostate cancer with finasteride: An Intergroup trial

CA Coltman Jr;P Feigl;IM Thompson Cancer Investigation 13(Suppl.1):43(#36)

Chemoprevention of prostate cancer.

IM Thompson;CA Coltman;OW Brawley;A Ryan Seminars in Urology 13(2):122-129

1994

Chemoprevention of prostate cancer with finasteride, an Intergroup trial

CA Coltman Jr;J Unger;IM Thompson Annals of Oncology [Corrigendum6(6)621-1995]5(Suppl.8):65(#P324)

Prostate cancer prevention: Risk reduction through life-style, diet, and chemoprevention

KE Greco;L Kulawiak Oncology Nursing Forum 21(9):1504-1511

The prostate cancer prevention trial. A low-risk, high-accrual study.

J O'Connor Oncology Issues 9(5):20-24

1993

Chemoprevention of prostate cancer with finasteride

I Thompson;P Feigl;C Coltman Cancer Prevention Dec:1-15